DPS wins contract for €100 million clinical manufacturing facility in the US
Engineering group DPS, alongside its US architectural partner TRIA, has won a major contract to work on Moderna Therapeutics’ new €100 million clinical manufacturing facility in Norwood, Massachusetts.
DPS is providing full architectural and engineering design, as well as project management services, for the 200,000 sq. ft. facility. The finished site will provide Good Manufacturing Practice (GMP) standards for the clinical manufacture of mRNA therapies.
The investment in the facility is a huge one for the clinical stage biotechnology company. Moderna Therapeutics will carry out all manufacturing activities at the site, from raw material production to active pharmaceutical ingredients, formulation, filling and finish.
The full range of services that DPS and TRIA are set to offer will ensure that the Norwood facility can manufacture, control and supply clinical grade mRNA therapies, which Moderna hope can create a new generation of transformative medicines.
DPS CEO Frank Keogh says: “This is a significant contract win for DPS and builds on the strong relationship we have developed with Moderna. We are proud to be supporting Moderna with this major investment in Norwood. This project demonstrates DPS’s ability to bid for and win large-scale capital investment design projects in the US.”
If Moderna’s therapies receive regulatory approval, the Norwood site will become the manufacturing base for these therapies to be supplied to patients worldwide.
Commenting on the project, senior vice president of manufacturing and operations at Moderna, Steve Harbin, said: “This is quite an ambitious project and will result in a truly unique facility… This will be among the most integrated end-to-end process facilities I have built and seen in my 25 years working in the pharmaceutical industry.”
Construction of the site is due to begin this month, with an estimated completion date of early 2018.
